Post-effective amendment to a registration statement that is not immediately effective upon filing

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.22.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Operating expenses:    
Research and development $ 20,257 $ 10,625
General and administrative 74,944 11,436
Settlement expense 21,366 39,486
Reimbursement of expenses from Relief Therapeutics (771) (10,160)
Total operating expenses 115,796 51,387
Loss from operations (115,796) (51,387)
Other (income) expenses:    
Gain on extinguishment of debt (121)  
Interest expense 18 56
Change in fair value of warrant liability (1,692)  
Change in fair value of Earnout Cash liability (20,938)  
Change in fair value of embedded put   27
Loss on conversion of convertible notes payable   307
Total other (income) expenses (22,733) 390
Loss before tax (93,063) (51,777)
Net loss (93,063) (51,777)
Deemed dividend - warrants (2,692)  
Deemed dividend - Earnout Shares (253,130)  
Net loss attributable to common stockholders $ (348,885) $ (51,777)
Net loss per share:    
Basic $ (1.98) $ (1.51)
Diluted (1.98) (1.51)
Net loss per share attributable to common stockholders:    
Basic (7.44) (1.51)
Diluted $ (7.44) $ (1.51)
Weighted average common shares outstanding:    
Basic 46,917,701 34,270,955
Diluted 46,917,701 34,270,955